Related articles - Bulevirtide:Application and safety
- Bulevirtide, a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta vir....
- Mar 29，2023
|
| | Bulevirtide Basic information |
| Product Name: | Bulevirtide | | Synonyms: | Bulevirtide;Bulevirtide (Myrcludex B);MyrB;Propofol Impurity 48 | | CAS: | 2012558-47-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Bulevirtide Structure]() |
| | Bulevirtide Chemical Properties |
| form | Solid | | color | White to off-white |
| | Bulevirtide Usage And Synthesis |
| Description |
Bulevirtide (BLV), the first-in-class entry inhibitor, is a 47-amino acid synthetic liner lipopeptide derived from the preS1 domain of the HBV large surface that targets the NTCP, the entry receptor for HBV/HDV. By blocking this receptor, new infections are prevented, and infected hepatocytes are replaced by naive cells that will be protected from infection. Consequently, viral spread in the liver is prevented.
| | Biological Activity | The sequence of Bulevirtide (BLV) is derived from that of preS1 from HBV genotype C (residues Gly2-Gly48) with a shortening of the 11 additional N-terminal amino acids and one amino acid substitution, Gln46Lys. BLV exhibits a remarkably high inhibitory constant (IC50?=?140 pM) against HBV and HDV in primary human hepatocytes and HepaRG cells. BLV has also been demonstrated to inhibit the NTCP-mediated uptake of bile salts but at an IC50 in the nanomolar range[1]. | | References |
[1] Liu, Hongtao et al. “Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.” Nature Communications 22 1 (2024).
|
| | Bulevirtide Preparation Products And Raw materials |
|